[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353441-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353441-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acquired-resistance-to-the-prmt5-inhibitor-confers-collateral-sensitivity-to-mek-inhibition-in-mtap-null-non-small-cell-lung-cancer","Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer","","Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while sparing MTAP-wildtype (MTAP-WT) cells. However, modest objective response rates suggest intrinsic or acquired resistance may limit benefit. This study models acquired resistance to BMS-986504/MRTX1719 and identifies MEK inhibition as a reproducible collateral vulnerability linked to resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acquired-resistance-to-the-prmt5-inhibitor-confers-collateral-sensitivity-to-mek-inhibition-in-mtap-null-non-small-cell-lung-cancer/353441/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acquired-resistance-to-the-prmt5-inhibitor-confers-collateral-sensitivity-to-mek-inhibition-in-mtap-null-non-small-cell-lung-cancer/353441.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapy challenge prompted this study of PRMT5 inhibitors?","Question",{"text":63,"@type":64},"Modest objective response rates indicate that intrinsic or acquired resistance may restrict clinical benefit of MTA-cooperative PRMT5 inhibitors. The study focuses on understanding acquired resistance in MTAP-null NSCLC models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is acquired resistance studied in this work?",{"text":68,"@type":64},"The authors use multiple in vitro-derived resistant models for MTAP-null non-small cell lung cancer cells, then compare sensitive and resistant cells using cross-resistance assessment and high-throughput drug screening.",{"name":70,"@type":61,"acceptedAnswer":71},"What collateral vulnerability emerged after resistance to MRTX1719?",{"text":72,"@type":64},"After acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells, resistant cells show increased sensitivity to MEK inhibitors. The phenotype is also supported by rewired MAPK-related transcriptional programs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353441,1790813395,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nAcquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition inMTAP-Null Non-Small Cell Lung Cancer  \nRongjie Fu 1,†, Yalong Wang 1,†, Ishita Rehman 1,2, Ella Bedford 1, Sana Sharif 3, Nghi D. Nguyen 4, Reid T. Powell 4, Andrew Adams 1, Weijun Liu 1, Shuyue Wang 1, Wei He 1, Yue Lu 1, Bin Liu 1,  \nPooja Anil Shah 5, Jordi Rodon Ahnert 5, Taiping Chen 1, Weiyi Peng 6, Clifford C. Stephan 4, Xinli Liu 3, Mark T. Bedford 1,* and Han Xu 1,7, *  \nAcademic Editor: Ajoy Basak  \nReceived: 31 May 2026  \nRevised: 10 August 2026  \nAccepted: 14 August 2026  \nPublished: 17 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA  \n2 Department of Biotechnology, The Neotia University, Sarisha 743368, West Bengal, India  \n3 Department of Pharmacological and Pharmaceutical Sciences, The University of Houston College of Pharmacy, Houston, TX 77204, USA  \n4 Texas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA  \n5 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n6 Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA  \n7 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA  \n* [Correspondence: mtbedford@mdanderson.org](Correspondence: mtbedford@mdanderson.org) (M.T.B.); [hxu4@mdanderson.org](hxu4@mdanderson.org) (H.X.)† These authors contributed equally to this work.  \nAbstract  \nProtein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while largely sparing MTAP-wildtype (MTAP-WT) cells, thereby improving tumor selectivity over first-generation PRMT5 inhibitors. Despite encouraging efficacy and safety signals in early clinical studies, the modest objective response rates (ORRs) observed with these inhibitors suggest that intrinsic or acquired resistance may limit their clinical benefit. Here, we investigated acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS- 986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance. Using multiple in vitroderived resistant models, we found that acquired resistance was accompanied by crossresistance to mechanistically distinct PRMT5 inhibitors. Notably, this phenotype was not fully explained by altered PRMT5 activity or changes in MTA levels. High-throughput drug screening of paired sensitive and resistant cells revealed increased sensitivity to MEK inhibitors following acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells. Consistently, resistant cells exhibited rewired MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as a reproducible collateral vulnerability associated with acquired MRTX1719 resistance in MTAP-null NSCLC models and support further evaluation of MEK inhibition as a potential treatment-switching strategy following resistance.  \nKeywords: PRMT5; MTAP-null; acquired resistance; MTA-cooperative PRMT5 inhibitor; MAPK signaling; MEK inhibition  \n1. Introduction  \nHomozygous deletion of chromosome 9p21.3 is one of the most frequent genomic alterations in human cancers. Among genes mapping to this region, the tumor suppressor cyclin-dependent kinase inhibitor 2A (CDKN2A) is the most frequently deleted gene (13.5%), followed by methylthioadenosine phosphorylase (MTAP) (9.3%) . Because of their close genomic proximity, MTA","cbCaiivp9Qa0Xgm0","https://ap.wps.com/l/cbCaiivp9Qa0Xgm0","pdf",32922770,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What therapy challenge prompted this study of PRMT5 inhibitors?\",\"answer\":\"Modest objective response rates indicate that intrinsic or acquired resistance may restrict clinical benefit of MTA-cooperative PRMT5 inhibitors. The study focuses on understanding acquired resistance in MTAP-null NSCLC models.\"},{\"question\":\"How is acquired resistance studied in this work?\",\"answer\":\"The authors use multiple in vitro-derived resistant models for MTAP-null non-small cell lung cancer cells, then compare sensitive and resistant cells using cross-resistance assessment and high-throughput drug screening.\"},{\"question\":\"What collateral vulnerability emerged after resistance to MRTX1719?\",\"answer\":\"After acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells, resistant cells show increased sensitivity to MEK inhibitors. The phenotype is also supported by rewired MAPK-related transcriptional programs.\"}]","Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer | PDF",1790105401,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4be1d9604226b430a3d6876a1284b4a2.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8c733f2ef34c7bcfd1e9a375dff01e4.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1019ddd523b2159121a07c323bd86dc.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff4f282e2209ab5138c62ea26cdfd5fc.webp",980,1385]